Globalpharma's Bold 2025 Expansion: 25 New Products

Dubai Investments PJSC, a prominent player in the UAE's investment landscape, has announced a major strategic move through its wholly-owned subsidiary, Globalpharma. The pharmaceutical manufacturer is set to launch 25 innovative products in 2025, targeting key therapeutic areas such as diabetes, cardiovascular, gastroenterology, and orthopaedics. This initiative underscores Globalpharma's commitment to addressing the evolving healthcare needs of the region with high-quality, accessible medications.

According to Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries & Masharie and Board Director of Globalpharma, the company's growth and innovation align perfectly with Dubai Investments' broader vision of transforming key industries. As the pharmaceutical sector continues to expand, the Group is strategically positioning Globalpharma to seize emerging opportunities, aiming to not only contribute to the regional healthcare ecosystem but also to establish Dubai Investments as a significant player on the global pharmaceutical stage.

Globalpharma's ambitious plans for 2025 are not just about product launches. The company is also focusing on strengthening its distribution network to ensure seamless access to its products. By optimizing delivery channels and forging new partnerships, Globalpharma is committed to meeting the needs of healthcare practitioners and patients alike. Furthermore, the company is refining its market entry strategies to adapt to the unique requirements of regional markets, solidifying its presence in key territories while exploring new opportunities.

Basem Albarahmeh, General Manager of Globalpharma, emphasized that the strategic focus for 2025 revolves around innovation, accessibility, and partnerships. The launch of 25 new products across critical therapeutic areas underscores the company's commitment to tackling the region's healthcare challenges. From enhancing its nutraceutical and women's health portfolios to expanding market access strategies, Globalpharma is laying the groundwork for long-term growth.

The momentum for 2025 builds on the success of 2024, which saw the launch of several innovative products, including Glovadip (Valsartan + Amlodipine) and RUSET (Rosuvastatin + Ezetimibe) for cardiovascular health, as well as Uriout (Febuxostat) for chronic gout management. This track record of innovation and strategic expansion positions Globalpharma as a formidable player in the pharmaceutical industry.

For investors, the ambitious expansion plans of Globalpharma, backed by Dubai Investments PJSC, present an exciting opportunity. The strategic alignment with regional healthcare needs and the focus on innovation and partnerships suggest a promising outlook. Therefore, considering the company's growth trajectory and strategic initiatives, the recommendation is to buy the instrument, as it is poised to deliver sustainable financial returns.